Cost-effectiveness of ribociclib as initial treatment for premenopausal women with advanced breast cancer in Singapore

Lydia Loke1 | Soo-Chin Lee2 | Fiona Pearce1 | Kwong Ng1 | Mohamed Ismail Abdul Aziz1

1Agency for Care Effectiveness (ACE), Ministry of Health, Singapore
2National University Cancer Institute (NCIS), Singapore

Correspondence
Kwong Ng, Agency for Care Effectiveness (ACE), Ministry of Health, 14 College Road, 169853 Singapore. Email: ng_kwong_hoe@moh.gov.sg (K. N.).

Abstract

Background: CDK4/6 inhibitors have shown promising results for treating advanced breast cancer (ABC) and are routinely used in Singapore. In view of their high costs, it is important to assess their relative value compared to existing standards of care in the local setting.

Aims: This study evaluates the cost-effectiveness of adding ribociclib to goserelin and a nonsteroidal aromatase inhibitor or tamoxifen as initial therapy for premenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) ABC in Singapore.

Methods: A partitioned survival model with four health states (progression-free on first-line treatment, progression-free on second-line treatment, progressed disease, and death) was developed from a healthcare system perspective over a 10-year time horizon. Key clinical inputs were derived from the MONALEESA-7 trial, and survival curves were extrapolated beyond the trial period. Health state utilities were derived from the literature and direct medical costs were obtained from local public healthcare institutions. A discount rate of 3% was applied to both costs and outcomes. One-way deterministic and probabilistic sensitivity analyses were conducted to explore uncertainties.

Results: The base-case analysis resulted in an incremental cost-effectiveness ratio (ICER) of SGD197,667 per quality-adjusted life-year. Sensitivity analyses showed that the ICER was sensitive to the survival parametric distribution, ribociclib price, time horizon, and utility weights used. Even when these were varied, ICERs remained high and not cost-effective in the local context.

Conclusion: At its current price, adding ribociclib to endocrine therapy is unlikely to be cost-effective in Singapore for HR+, HER2− ABC. Results from this study are useful to inform future funding decisions for CDK4/6 inhibitors alongside other factors including clinical effectiveness, safety, and budget impact considerations.
1 | BACKGROUND

Breast cancer is the most prevalent cancer among women in Singapore, accounting for 29% ($n=10,824$) of all female cancers from 2013 to 2017.\(^1\) It was also the leading cause of cancer-related deaths among women in Singapore (17% of all cancer deaths in women) for the same period.\(^2\) While breast cancer is predominantly diagnosed in postmenopausal women, breast cancer rates in premenopausal women have been increasing. In Asia, more than 40% of breast cancers are diagnosed in women <50 years, compared with 20% in Western countries.\(^3\) Hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) is the most common breast cancer subtype\(^4\) and younger women with HR+ tumors tend to have a poorer prognosis than older women.\(^5\)

Cyclin-dependent kinase (CDK)4/6 inhibitors (palbociclib, ribociclib, and abemaciclib) have shown promising results and have transformed the treatment landscape for HR+, HER2– advanced breast cancer (ABC). They are increasingly being used as standard of care with endocrine therapy (ET) in both first- and later-line settings. While there are no head-to-head trials comparing CDK4/6 inhibitors with each other, they have demonstrated remarkably similar efficacy but different toxicity profiles. Palbociclib and ribociclib are associated with more myelosuppression whereas diarrhea is more common with abemaciclib. Ribociclib has been associated with QT prolongation, and hepatic dysfunction was reported with both ribociclib and abemaciclib.\(^6\) As the current market leader in Singapore, palbociclib is most commonly used locally and is preferred due to fewer monitoring requirements compared to other agents. To date, none of the phase 3, first-line studies of CDK4/6 inhibitors have reported overall survival (OS) results or have been studied in premenopausal women except for ribociclib, which demonstrated a significant OS benefit in MONALEESA-7.\(^7\)

Published cost-effectiveness analyses (CEAs) of palbociclib and ribociclib so far have focused on postmenopausal women and have consistently reported high incremental cost-effectiveness ratios (ICERs) based on immature OS data or data from a phase 2 study which showed no OS benefit.\(^8\)-\(^13\) With the OS results seen with MONALEESA-7, we hypothesized that this could improve cost-effectiveness of this treatment strategy. This study evaluates the cost-effectiveness of first-line ribociclib with ET in premenopausal women, an underrepresented but previously important subgroup of patients in Singapore.

2 | METHODS

Clinical inputs for the model were mainly derived from the MONALEESA-7 study. At a median follow-up of 34.6 months, ribociclib was associated with significantly improved progression-free survival (PFS; hazard ratio [HR] = 0.55, 95% CI 0.44 to 0.69; $p < .0001$) and OS (HR = 0.71, 95% CI 0.54 to 0.95; $p = .00973$).\(^8\)-\(^14\)

2.1 | Model structure

An Excel-based partitioned survival (areas under the curve) model was developed from the Singapore healthcare system perspective (comprising government subsidies, insurance, and patient co-payments) to assess the cost-effectiveness of adding ribociclib to first-line ET (goserelin plus either letrozole, anastrozole, or tamoxifen) compared to ET alone (placebo) in premenopausal women with HR+, HER2– ABC. The model included four health states: first-line progression-free (PF1), second-line progression-free (PF2), progressed disease on second- or subsequent-line treatment (PD), and death (Figure S1). All patients were assumed to enter the model in the PF1 state. The proportion of patients in each health state at each time point was calculated from the Kaplan-Meier (KM) OS and PFS curves from the MONALEESA-7 trial. At the beginning of each cycle, patients remained in the PF1 state until they progressed and transitioned to PF2 or died. Second-line PF (PF2) represented the time to disease progression between first- and second-line treatment cessation. In the PF2 state, patients received a second-line treatment and stayed in this state until their disease progressed, and they transitioned to the PD state, or until they died. The PD state represented the time from second-line therapy cessation until death, and in this state, patients received subsequent lines of treatment, and/or supportive or palliative care. A time horizon of 10 years with a cycle length of 28 days was used in the base case, which was deemed to be sufficiently long enough to capture most of the survival benefits and costs accrued, considering that the 10-year survival rate for women (<50 years) with ABC is approximately 15%.\(^15\) A discount rate of 3% was applied to both health outcomes and costs.

2.1.1 | Treatment pathway

Patients were assumed to receive either ribociclib $600\text{ mg (3 \times 200 mg tablets)}$ orally once daily for 21 days followed by a 7-day break every 28 days or placebo in addition to goserelin and either letrozole, anastrozole, or tamoxifen until disease progression. Choice of ET, and distributions of second-, third-, and subsequent line therapies or “treatment mix” were extrapolated from MONALEESA-7 in the base case (Table S1). Of note, in the trial, only 69% and 75% of patients in the ribociclib and placebo arms, respectively, received second-line treatment which is lower than local practice where 95% of patients would proceed to second-line treatment. In both the trial and local practice, we assumed approximately 85% of patients would proceed to third or subsequent line treatment. According to local experts, the treatment pathway for ABC is complex and choice of second- and subsequent line therapies is highly variable and thus “treatment mix” was varied in a scenario analysis to capture the likely treatments used locally in patients who received ET with or without a CDK4/6 inhibitor as initial therapy (Table S1).

2.2 | Model parameters

2.2.1 | Clinical efficacy data

Areas under the PFS and OS curves in MONALEESA-7 were used to determine the mean time that patients remained in each health state. As patient level data were not available, individual data points from the
published KM curves for PFS and OS were extracted using the WebPlotDigitizer and the Guyot curve fitting approach was used to estimate the underlying survival distribution from the digitized KM graphs. Actual data from the KM curves were used until the end of the 3-year follow-up period, after which parametric functions were fitted onto the remaining data to extrapolate the long-term survival until the end of the time horizon. Candidate functions for the parametric extrapolation were the exponential, Weibull, log-normal, log-logistic, Gompertz, and generalized gamma distributions. Goodness-of-fit of these functions were assessed using the Akaike Information Criterion (AIC) and a visual inspection of the parametric curves against actual data. For OS, the AIC scores for the log-logistic and Gompertz distributions were the lowest among the six candidate functions for ribociclib and placebo, respectively (Table S2). However, extrapolated data from these distributions led to clinically unlikely survival endpoints (53% for ribociclib, [Figure S2] 19% for placebo [Figure S3], respectively, after 5 years) relative to reported local 5-year OS rates for women with metastatic breast cancer (27%) and survival rates from outside Singapore (up to 40%). Furthermore, overseas registries have also reported 10-year breast cancer-specific survival rates ranging from 15% to 16%, which also deviated from these distributions at this time point (28% for ribociclib [Figure S2] 0% for placebo [Figure S3]). In both treatment arms, the Weibull distribution had the next lowest AIC scores and fitted well with the actual curves with more realistic 5- and 10-year OS rates of 39% and 8% for placebo and 49% and 15% for ribociclib, respectively. Considering both visual fit and clinical plausibility, the Weibull distribution was chosen for the base-case analysis to extrapolate OS for both treatment arms.

For PFS, visual inspection and AIC values (Tables S3 and S4) showed that the distributions fitted well with the actual KM curves. However, only the Weibull and exponential distributions for PF1 and Weibull and generalized gamma for PF2 were clinically plausible for both treatment arms as all other distributions had elongated tail ends (Figures S4–S7). The Weibull distribution for both PF1 and PF2 were chosen for the base case.

As patients were not allowed to continue study treatment on disease progression in the trial, and disease progression was the most common reason for treatment discontinuation (75%-80%), PFS curves were also used to estimate time on treatment. The difference between PF2 and PF1 PFS curves was used to estimate treatment and disease management costs for patients receiving second-line treatment in the model. As time spent on third and subsequent line therapies was not available and assuming that most patients remained on active treatment until they died, time spent on third and subsequent line therapies was subsumed within the PD state and was estimated as the difference between OS and PF2. In the absence of long-term data, the treatment effect of ribociclib was assumed to last for the entire time horizon with scenario analyses limiting treatment effect to 5 and 7 years to account for this uncertainty.

2.2.2 Utility values

Although utility data were collected in MONALEESA-7 using the European Quality of Life Five Dimensions (EQ-5D) questionnaire, they were not publicly available, and an indirect method was used to estimate the quality-adjusted life-years (QALYs) in the model. A literature search was conducted to identify utility studies in patients with ABC. Two breast cancer utility studies matching our target population were retrieved—a local study using vignettes and the standard gamble (SG) method to measure patient preferences and a Canadian study using the EQ-5D questionnaire to derive health state utility values (HSUVs) (Table S5). The Canadian study was selected for use in the base case as participants most closely resembled the disease characteristics and health states of the trial population. Moreover, EQ-5D is the preferred instrument for utility elicitation by several health technology assessment (HTA) agencies. A scenario analysis was conducted using the local HSUVs to assess their impact on the ICER.

In MONALEESA-7, patients in the ribociclib arm experienced more grade ≥ 3 neutropenia, hepatotoxicity, and prolonged QT interval than those in the placebo arm (Table 1). As local experts advised that these adverse events (AEs) were manageable and unlikely to affect quality of life, utility decrements for AEs were not included in the model.

2.2.3 Resource use and cost data

Only direct medical costs were included in the model, in accordance with the perspective of the analysis. Indirect costs (eg, productivity loss) were not considered. Disease management costs for both treatment arms included cost of drugs, drug administration, pharmacy preparation, medical consultations, CT scans, AE hospitalizations, and end-of-life care. Additional laboratory tests, such as full blood counts, liver function tests, and renal panels, as well as AEs were included in the model. Hospitalization costs were obtained from the Ministry of Health Singapore Casemix and subvention databases (2011-2018). Costs were based on AE rates in MONALEESA-7 and associated hospitalization rates estimated by local experts (Table 1). These costs were applied once to the total life-time costs in the model. Terminal care costs for palliative treatment such as inpatient hospice or home-care hospice visits were also included for the last 28 days of life for each patient who died in the model.

2.2.4 Outcomes

The outcomes of interest were overall life years (LYs), QALYs, the total costs in both treatment arms, and the ICER.
Sensitivity analyses

One-way sensitivity analyses (OWSA) were conducted to explore the impact of uncertain model parameters on the ICER. Each parameter was varied independently by the lower and upper limits of the 95% confidence interval or reported ranges in literature.
A probabilistic sensitivity analysis (PSA) was performed to explore the uncertainty of input parameters through random sampling from assigned distributions. Probability distributions were selected according to the nature of the variable. HSUVs were assumed to follow a beta distribution while survival functions for PFS and OS were sampled from a multivariate normal distribution via the Cholesky decomposition matrix. Drug costs and cost of routine clinical care (ie, medical consultation visits, laboratory tests, etc.) were assumed to be certain and thus not varied in the PSA. Monte Carlo iterations were repeated over 15 000 iterations to generate an ICER distribution in a scatterplot. In addition, a cost-effectiveness acceptability curve (CEAC) was obtained showing the probability of cost-effectiveness of both treatments over a range of hypothetical willingness-to-pay (WTP) thresholds.

### Results

#### 3.1 Base-case analysis

The base-case analysis over a time horizon of 10 years showed that adding ribociclib to goserelin and an aromatase inhibitor or tamoxifen

| TABLE 2 | Summary of costs and benefits of adding ribociclib to endocrine therapy, base-case analysis |
|-----------------|-----------------------------------------------|
| **Ribociclib + ET** | **ET alone** | **Incremental difference** |
| Total cost (SGD) | $177,589 | $87,119 | $90,470 |
| Drug and management costs | $174,987 | $84,420 | $90,567 |
| Terminal care costs | $2,433 | $2,641 | $-208 |
| AE costs | $169 | $58 | $111 |
| **Total benefit** | | | |
| QALYs | 3.4386 | 2.9810 | 0.4577 |
| LYS | 4.8739 | 4.2416 | 0.6323 |
| PFLYs | 2.3210 | 1.5810 | 0.7401 |
| ICER (QALY) | $197,667 |
| ICER (LY) | $143,080 |

Abbreviations: AE, adverse event; ET, endocrine therapy; ICER, incremental cost-effectiveness ratio; LY, life-year; PFLY, progression free life year; QALY, quality-adjusted life year; SGD, Singapore Dollar.

**FIGURE 1** Tornado diagram of OWSA of the effect of the seven most influential variables on the cost effectiveness results of ribociclib plus endocrine therapy versus placebo plus endocrine therapy. Vertical axis represents the base-case ICER while the horizontal axis represents the change in ICER relative to base case for variables subjected to OWSA. Numbers in brackets represent the deterministic value of each parameter, followed by the lower and upper bounds of the value used in the OWSA. PD, progressed disease on second and subsequent lines of treatment; PF1, progression-free state on first-line treatment; PF2, progression-free state on second-line treatment.
increased both effectiveness and costs, resulting in an ICER of SGD197,667/QALY and SGD143,080/LY gained (Table 2).

3.2 | Sensitivity analyses

OWSA confirmed that the ICER was most sensitive to the utilities in PF1, followed by the cost of ribociclib (Figure 1). The Tornado diagram showed that there were no instances whereby the ICER fell below SGD100,000/QALY gained except when the cost of ribociclib was reduced. The ICER remained unfavorably high across the range of possible model parameter values assumed.

Results from the PSA simulation were congruent with the base-case analysis demonstrating that adding ribociclib to ET was consistently more effective and costlier than ET alone. The mean ICER for ribociclib plus ET was marginally higher than the base-case ICER at SGD199,918/QALY gained. The CEAC showed that ribociclib had zero probability of being cost-effective when the WTP threshold was below SGD198,000/QALY (Figure 2).

3.3 | Scenario analyses

Additional scenario analyses were performed to examine how base-case assumptions affected the ICER (Table 3). In the absence of any price reduction for ribociclib, all scenario analyses showed exceedingly high ICERs. Even with a 50% reduction in the price of ribociclib, the ICER remained high at SGD102,964/QALY. Applying a log-logistic parametric fit to the ribociclib OS curve and extending the time horizon to 15 years produced lower ICERs compared to the base-case scenario and using local HSUVs and limiting the treatment effect of ribociclib resulted in higher ICERs (Table 3). Changing the treatment mix for second and subsequent lines of therapy based on local treatment patterns had a significant impact on the ICER, potentially reducing the ICER to SGD111,066/QALY. Given the high proportion of patients switching to palbociclib after disease progression in the comparator arm and the significantly higher list prices of palbociclib and abemaciclib than ribociclib, the local treatment scenario was also modeled using a single price across all CDK4/6 inhibitors, resulting in an ICER of SGD140,102/QALY.

4 | DISCUSSION

To our best knowledge, this is the first study addressing the cost-effectiveness of a CDK4/6 inhibitor for HR+, HER2− ABC in Singapore. Although MONALEESA-7 demonstrated a significant OS benefit with the addition of ribociclib to first-line ET in premenopausal women, our analyses revealed that this treatment combination does not represent a cost-effective use of healthcare resources at its
There may be several reasons for this. Firstly, the lifetime drug cost per patient in the PF1 health state was SGD122,887 for ribociclib with ET compared to SGD21,961 for ET alone. The high ICER was primarily driven by the longer PFS in the ribociclib arm and the large cost difference between ribociclib (SGD2,929) and ET (SGD2 and SGD10 for tamoxifen and letrozole, respectively) for each 28-day cycle, resulting in high incremental costs. Secondly, on close examination, the OS curves of both treatment arms in MONALEESA-7 were quite similar up until 2 years, after which, they began to diverge. Consequently, despite the statistically significant OS

| TABLE 3  | Summary of cost and benefit in the scenario analyses |
|----------|------------------------------------------------------|
|          | Cost (SGD)  | QALYs | LYs  | PFLYs | ICER (SGD/QALY) |
| Base case|            |       |      |       |                 |
| Ribociclib + ET | 177,589 | 3.4386 | 4.8739 | 2.3210 | 197,667         |
| ET alone      | 87,119   | 2.9810 | 4.2416 | 1.5810 |                 |
| Survival curve parametric fit | | | | | |
| Log-logistic fit (OS ribociclib arm) | | | | | |
| Ribociclib + ET | 184,474 | 3.7008 | 5.2836 | 2.3210 | 135,238         |
| ET alone      | 87,119   | 2.9810 | 4.2416 | 1.5810 |                 |
| Time horizon (15 years) | | | | | |
| Ribociclib + ET | 183,303 | 3.6206 | 5.1528 | 2.3314 | 165,239         |
| ET alone      | 90,051   | 3.0562 | 4.3582 | 1.5831 |                 |
| Utility weights reference source | | | | | |
| Utilities from Tan et al. | | | | | |
| Ribociclib + ET | 177,589 | 2.2782 | 4.8739 | 2.3210 | 210,488         |
| ET alone      | 87,119   | 1.8484 | 4.2416 | 1.5810 |                 |
| Ribociclib treatment effect | | | | | |
| Limit to 5 years | | | | | |
| Ribociclib + ET | 174,716 | 3.3295 | 4.7035 | 2.3210 | 251,289         |
| ET alone      | 87,119   | 2.9810 | 4.2416 | 1.5810 |                 |
| Limit to 7 years | | | | | |
| Ribociclib + ET | 176,643 | 3.4010 | 4.8151 | 2.3210 | 213,133         |
| ET alone      | 87,119   | 2.9810 | 4.2416 | 1.5810 |                 |
| Second and subsequent lines of treatment | | | | | |
| Local treatment algorithm (using list prices for CDK4/6 inhibitors) | | | | | |
| Ribociclib + ET | 205,388 | 3.4386 | 4.8739 | 2.3210 | 111,066         |
| ET alone      | 154,554  | 2.9810 | 4.2416 | 1.5810 |                 |
| Local treatment algorithm (using a single price$ across all CDK4/6 inhibitors) | | | | | |
| Ribociclib + ET | 203,086 | 3.4386 | 4.8739 | 2.3210 | 140,102         |
| ET alone      | 138,963  | 2.9810 | 4.2416 | 1.5810 |                 |
| Pricing scenario | | | | | |
| 25% price reduction | | | | | |
| Ribociclib + ET | 155,495 | 3.4386 | 4.8739 | 2.3210 | 150,316         |
| ET alone      | 86,697   | 2.9810 | 4.2416 | 1.5810 |                 |
| 50% price reduction | | | | | |
| Ribociclib + ET | 133,401 | 3.4386 | 4.8739 | 2.3210 | 102,964         |
| ET alone      | 86,276   | 2.9810 | 4.2416 | 1.5810 |                 |
| 75% price reduction | | | | | |
| Ribociclib + ET | 111,307 | 3.4386 | 4.8739 | 2.3210 | 55,612          |
| ET alone      | 85,854   | 2.9810 | 4.2416 | 1.5810 |                 |

Abbreviations: ET, endocrine therapy; ICER, incremental cost-effectiveness ratio; LY, life-year; OS, overall survival; PFLY, progression free life year; QALY, quality-adjusted life year; SGD, Singapore Dollar.

$The list price of ribociclib was used across all CDK4/6 inhibitors.
benefit, the magnitude of the modeled survival gain was insufficient to produce a favorable ICER.

OWSA assessing model key drivers revealed that the ICER was most sensitive to the HSUVs for the PF1 health state. As HSUVs were not directly available from the trial, an indirect method was used to estimate the QALYs in the model. Base-case HSUVs were obtained from a published Canadian quality of life study in patients with HR+, HER2− ABC where the EQ-5D questionnaire was used to derive utilities. EQ-5D is a preferred instrument for utility elicitation by several HTA agencies and has often been used in breast cancer and local CEAs. As a generic measure, EQ-5D is better suited for health policy decisions and funding allocation as it allows for comparisons across disease areas and health technologies. As country settings may affect HSUVs, a scenario analysis was conducted based on local HSUVs which resulted in a significantly higher ICER driven by lower local HSUVs in the PF1 health state.

Our base-case model had a time horizon of 10 years, which was lower than other published CEAs which used 15- to 40-year time horizons. A 10-year time horizon was selected as the local 5-year survival rate for stage IV breast cancer was 27%. A longer time horizon than 10 years would have increased the model uncertainty as only 3 years of trial data was available and the model would have largely been based on extrapolation. A scenario analysis using a 15-year time horizon reduced the ICER to SGD165,239/QALY.

The PSA generated a similarly high ICER as the base case. The CEAC demonstrated that for a WTP threshold of up to SGD198,000/QALY, ET alone was the more cost-effective treatment option. While Singapore does not have an explicit WTP threshold to determine whether a drug represents good value for money, the wide variation in the upper and lower limits of the high base-case ICER from sensitivity and scenario analyses provides a strong indication that the addition of ribociclib is unlikely to represent a cost-effective treatment option in the local context.

Our results are comparable with overseas cost-effectiveness studies which found palbociclib or ribociclib were not cost-effective in the first-line setting, with ICERs ranging between USD100,000-770 000/QALY. We did not compare the cost-effectiveness of ribociclib with other CDK4/6 inhibitors but several studies have reported that ribociclib is either cost-saving or cost-effective compared to palbociclib. Of note, as none of the phase 3, first-line CDK4/6 inhibitor studies have reported mature OS results, all published CEAs were either based on immature OS data or data from, a small phase 2 trial which did not show an OS benefit.

For patients whose disease progress on ET, there is a lack of data on the most effective treatment pathway leading to highly variable treatment strategies. We used the subsequent treatments reported in MONALEESA-7 to calculate treatment costs in the base case and modified the treatment mix in a scenario analysis based on local clinician input. Changing the treatment mix had a significant impact on the overall ICER, reducing it by over SGD80,000/QALY. The higher proportion of patients receiving high-cost second and subsequent line treatments (eg, CDK4/6 inhibitors, olaparib, or alpelisib) in the comparator arm in the local setting vs MONALEESA-7 could have led to this difference. Notably, the list prices for palbociclib and abemaciclib were significantly higher than for ribociclib. When these prices were lowered to match the price of ribociclib, the ICER in the local setting increased by almost SGD30,000/QALY. Given the high variability in treatment strategies and drug prices, the generated ICER based on local treatment mix is highly uncertain.

Our analysis has several limitations. Firstly, about 30% of women in MONALEESA-7 did not receive second-line treatment which is unlike the local setting where only about 5% of patients do not proceed to second-line therapy. In addition, only 20% of women in the placebo arm received subsequent treatment with a CDK4/6 inhibitor, whereas local clinicians report up to 50% of patients who do not receive a CDK4/6 inhibitor as initial therapy, will receive one following progression. The impact of these differences on survival is unknown and although we modeled the impact of using local treatment mixes on treatment costs, we did not change the survival curves which were based on MONALEESA-7. Secondly, we extrapolated survival curves from available trial data of approximately 3 years to a 10-year time horizon and the uncertainty of this extrapolation is unknown. We examined the impact of using different parametric extrapolations on the ICER and limiting the treatment effect duration to 5 or 7 years. We explored the log-logistic distribution for the ribociclib OS curve as it had a good fit and lowest AIC. While this scenario favored ribociclib treatment, the ICER still remained above SGD100,000/QALY. As expected, limiting the treatment effect duration to 5 or 7 years increased the ICER. Thirdly, we used the average prices of drugs at PHIs which did not include discounts offered by the manufacturers to some patients through patient access schemes. As details of these schemes and the number of patients enrolled were not publicly available these discounts were not included in the model which could have over-estimated treatment costs for some of the high-cost treatments used in the second or later line settings.

In conclusion, at its current list price, adding ribociclib to ET is unlikely to be cost-effective in Singapore when used in the first-line setting for HR+, HER2− premenopausal ABC. The similar efficacy of CDK4/6 inhibitors seen across trials suggests that their clinical effectiveness is comparable and independent of menopausal status. Therefore, palbociclib and abemaciclib are also unlikely to be cost-effective as they are priced higher than ribociclib. As CDK4/6 inhibitors are routinely used locally, results from this cost-effectiveness analysis will be useful to inform future value-based pricing discussions with manufacturers and national subsidy recommendations which also consider clinical effectiveness, safety and budget impact.

**ETHICAL STATEMENT**

Institutional ethics approval and patient consent were not required for this study.

**CONFLICT OF INTEREST STATEMENT**

LL, FP, KN, and MIAZ declare that they have no conflict of interest. SCL has served on the advisory boards for Pfizer (palbociclib), Novartis (ribociclib), and Eli Lilly (abemaciclib), has been an invited speaker for Pfizer (palbociclib) and Novartis (ribociclib) and has received research grants from Pfizer (palbociclib).
AUTHOR CONTRIBUTIONS
Lydia Loke: Conceptualization; formal analysis; methodology; project administration; visualization; writing-original draft; writing-review and editing. Soo Chin Lee: Resources; validation; visualization; writing-review and editing. Fiona Pearce: Conceptualization; supervision; visualization; writing-review and editing. Kwong Ng: Conceptualization; supervision; visualization; writing-review and editing. Mohamed Aziz: Conceptualization; formal analysis; methodology; supervision; validation; visualization; writing-review and editing.

DATA AVAILABILITY STATEMENT
The data that supports the findings of this study are available in the supplementary material of this article.

ORCID
Lydia Loke https://orcid.org/0000-0002-9681-293X
Soo-Chin Lee https://orcid.org/0000-0002-5835-6419
Kwong Ng https://orcid.org/0000-0002-6511-1639
Mohamed Ismail Abdul Aziz https://orcid.org/0000-0003-3606-7672

REFERENCES
1. National Registry of Diseases Office. Singapore Cancer Registry 50th Anniversary Monograph (1968–2017). 2019.
2. Youlden DR, Cramb SM, Yip CH, Baade PD. Incidence and mortality of female breast cancer in the Asia-Pacific region. Cancer Biol Med. 2014;11(2):101-115.
3. Yap YS, Singh AP, Lim JHC, et al. Elucidating therapeutic molecular targets in premenopausal Asian women with recurrent breast cancers. Npj Breast Cancer. 2018;4(1):19.
4. Partridge AH, Hughes ME, Warner ET, et al. Subtype-dependent relationship between young age at diagnosis and breast cancer survival. J Clin Oncol. 2016;34(27):3308-3314.
5. Hortobagyi GN, Stemmer SM, Burris HA, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol. 2018;29(7):1541-1547.
6. Johnston S, Martin M, Di Leo A, et al. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. Npj Breast Cancer. 2019;5(1):1-8.
7. Rugo HS, Finn RS, Diéras V, et al. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. Breast Cancer Res Treat. 2019;174(3):719-729.
8. Im SA, Lu YS, Bardia A, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med. 2019;381(4):307-316.
9. Mamiya H, Tahara RK, Tolaney SM, Choudhry NK, Najafzadeh M. Cost-effectiveness of palbociclib in hormone receptor-positive advanced breast cancer. Ann Oncol. 2017;28(8):1825-1831.
10. Matter-Walstra K, Ruhstaller T, Klingbiel D, Schwenkglenks M, Dedes KJ. Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK). Breast Cancer Res Treat. 2016;158(1):51-57.
11. Raphael J, Helou J, Pritchard KI, Naimark DM. Palbociclib in hormone receptor positive advanced breast cancer: a cost-utility analysis. Eur J Cancer. 2017;85:146-154.
12. Mistry R, May JR, Suri G, et al. Cost-effectiveness of ribociclib plus letrozole versus palbociclib plus letrozole and letrozole monotherapy in the first-line treatment of postmenopausal women with HR+/HER2-advanced or metastatic breast cancer: a U.S. payer perspective. J Manag Care Spec Pharm. 2018;24(6):S14-S23.
13. Zhang B, Long EF. Cost-effectiveness analysis of palbociclib or ribociclib in the treatment of advanced hormone receptor-positi ve, HER2-negative breast cancer. Breast Cancer Res Treat. 2019;175(3):775-779.
14. Tripathy D, Im SA, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018;19(7):904-915.
15. Eng LG, Dawood S, Sopik V, et al. Ten-year survival in women with primary stage IV breast cancer. Breast Cancer Res Treat. 2016;160(1):145-152.
16. Rohatgi A. WebPlotDigitizer Version 4.2. http://arohatgi.info. Accessed November 6, 2019.
17. Guyot P, Ades A, Ouwens MJ, et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12(1):9.
18. Oguya R, Sagara Y, Nikiura N, et al. Impact of subtype on survival of young patients with stage IV breast cancer. Clin Breast Cancer. 2019;19(3):200-7 e1.
19. Tan XY, Aung MM, Ngai MI, Xie F, Ko Y. Assessment of preference for hormonal treatment-related health states among patients with breast cancer. Value Health Reg Issues. 2014;3(1):27-32.
20. Lambert-Obry V, Gouault-Laliberté A, Castonguay A, et al. Real-world patient- and caregiver-reported outcomes in advanced breast cancer. Curr Oncol. 2018;25(4):e282-e290.
21. National Institute for Health and Care Excellence, United Kingdom. Guide to methods of technology appraisal. 2013. www.nice.org.uk/process/pmg9/chapter/foreword. Accessed July 27, 2020.
22. EUnetHTA. Methods for health economic evaluations - a guideline based on current practices in Europe. 2015. www.eunethta.eu/eunethta-methodological-guideline-methods-for-health-economic-evaluations. Accessed July 27, 2020.
23. Health Sciences Authority, Singapore. Package insert for Kisqali (ribociclib) (version dated 14 Feb 2020). 2020. https://eservice.hsa.gov.sg/prism/common/enquirepub/SearchDRBProduct.do?action=load&ga=2.183810082.563179921.1554083187-551332391.1551944793. Accessed July 27, 2020.
24. Health Sciences Authority, Singapore. Package insert for Ibrance (palbociclib) (version dated 20 Feb 2020). 2020. https://eservice.hsa.gov.sg/prism/common/enquirepub/SearchDRBProduct.do?action=load&ga=2.183810082.563179921.1554083187-551332391.1551944793. Accessed July 27, 2020.
25. Health Sciences Authority, Singapore. Package insert for Verzenio (abemaciclib) (version dated 27 Mar 2020). 2020. https://eservice.hsa.gov.sg/prism/common/enquirepub/SearchDRBProduct.do?action=load&ga=2.183810082.563179921.1554083187-551332391.1551944793. Accessed July 27, 2020.
26. Health Sciences Authority, Singapore. Package insert for Afinitor (everolimus) (version dated 19 Jul 2018). 2018. https://eservice.hsa.gov.sg/prism/common/enquirepub/SearchDRBProduct.do?action=load&ga=2.183810082.563179921.1554083187-551332391.1551944793. Accessed July 27, 2020.
27. Health Sciences Authority, Singapore. Package insert for Lynparza (olaparib) (version dated 30 Mar 2020). 2020. https://eservice.hsa.gov.sg/prism/common/enquirepub/SearchDRBProduct.do?action=load&ga=2.183810082.563179921.1554083187-551332391.1551944793. Accessed July 27, 2020.
28. Cholesky Decomposition: International Encyclopedia of the Social Sciences. www.encyclopedia.com/social-sciences/applied-and-social-sciences-magazines/cholesky-decomposition. Cited May 29, 2020
29. Hao Y, Wolfram V, Cook J. A structured review of health utility measures and elicitation in advanced/metastatic breast cancer. ClinicoEcon Outcomes Res. 2016;8:293-303.
30. Aziz MIA, Tan LE, Tan WHG, et al. Cost-effectiveness analysis of pembrolizumab monotherapy versus chemotherapy for previously untreated advanced non-small cell lung cancer. J Med Econ. 2020;23(9):952–960.
31. Pruis SL, Aziz MIA, Pearce F, Tan MH, Wu DBC, Ng K. Cost-effectiveness analysis of Sunitinib versus interferon-alfa for first-line treatment of advanced and/or metastatic renal cell carcinoma in Singapore. Int J Technol Assess Health Care. 2019;35(2):126–133.
32. Tan PT, Aziz MIA, Pearce F, Lim WT, Wu DBC, Ng K. Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer’s perspective. BMC Cancer. 2018;18(1):352.
33. Galve-Calvo E, González-Haba E, Gostkowicz J, Martínez I, Pérez-Mitru A. Cost-effectiveness analysis of ribociclib versus palbociclib in the first-line treatment of HR+/HER2– advanced or metastatic breast cancer in Spain. ClinicoEcon Outcomes Res. 2018;10:773-790.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section at the end of this article.

How to cite this article: Loke L, Lee S-C, Pearce F, Ng K, Aziz MIA. Cost-effectiveness of ribociclib as initial treatment for premenopausal women with advanced breast cancer in Singapore. Cancer Reports. 2021;4:e1308. https://doi.org/10.1002/cnr2.1308